GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akebia Therapeutics Inc (NAS:AKBA) » Definitions » Price-to-Free-Cash-Flow

Akebia Therapeutics (Akebia Therapeutics) Price-to-Free-Cash-Flow : N/A (As of Apr. 26, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics Price-to-Free-Cash-Flow?

As of today (2024-04-26), Akebia Therapeutics's share price is $1.33. Akebia Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.13. Hence, Akebia Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Akebia Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 12 years, Akebia Therapeutics's highest Price-to-Free-Cash-Flow Ratio was 22.80. The lowest was 6.31. And the median was 9.01.

AKBA's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.19
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Akebia Therapeutics's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.01. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.13.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 46.10% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 39.50% per year.

During the past 12 years, Akebia Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 46.10% per year. The lowest was -41.00% per year. And the median was 9.60% per year.


Akebia Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Akebia Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akebia Therapeutics Price-to-Free-Cash-Flow Chart

Akebia Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Akebia Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Akebia Therapeutics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Akebia Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akebia Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akebia Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Akebia Therapeutics's Price-to-Free-Cash-Flow falls into.



Akebia Therapeutics Price-to-Free-Cash-Flow Calculation

Akebia Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=1.33/-0.126
=N/A

Akebia Therapeutics's Share Price of today is $1.33.
Akebia Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.13.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Akebia Therapeutics  (NAS:AKBA) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Akebia Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Akebia Therapeutics (Akebia Therapeutics) Business Description

Traded in Other Exchanges
Address
245 First Street, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.
Executives
Ellen Snow officer: SVP, CFO and Treasurer C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Michel Dahan officer: SVP, Chief Business Officer C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Nicole R. Hadas officer: SVP, General Counsel, Sec. 20 PILGRAM DRIVE, WINCHESTER MA 01890
David A Spellman officer: SVP, CFO and Treasurer 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Steven Keith Burke officer: SVP, Chief Medical Officer 82 WILLIS ROAD, SUDBURY MA 01776
John P. Butler director, officer: CEO & President C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Violetta Cotreau officer: SVP, Chief Accounting Officer 245 FIRST STREET, 14TH FLOOR, CAMBRIDGE MA 02142
Ron Frieson director 245 FIRST STREET, 14TH FLOOR, CAMBRIDGE MA 02142
Dell Faulkingham officer: CCO C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
Leanne M Zumwalt director C/O THE ADVISORY BOARD CO WATERGATGE, 600 NEW HAMPSHIRE AVE NW, WASHINGTON DC 20037
Maxine Gowen director
Cynthia Smith director 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Myles Wolf director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
Karen L Tubridy officer: SVP, Chief Development Officer ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142